Fungal Research Trust
medical community awareness advocacy fungal diseases news

Media Centre

PUR1900 - new inhaled anti-infective to treat fungal infections associated with cystic fibrosis

June 22 2015

Pulmatrix, Inc. have announced a  new drug candidate, PUR1900,which is an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF). Pulmatrix is strategically focused on developing innovative, first-in-class inhaled therapies for rare pulmonary diseases. Fungal lung infections are difficult to treat, so methods for safely delivering effective agents directly to the lung address an important unmet medical need. 

PUR1900 is a dry powder formulation of a large, complex anti-fungal compound that can be administered at high therapeutic dose to the lung while minimizing systemic side effects; in contrast, oral anti-fungal medicines that have limitations in patients with CF due to long treatment regimen and serious systemic side effects. PUR1900 also has potential applications in other immunocompromised patients who have fungal lung infections.

"Approximately 15% of CF patients have acute bronchopulmonary aspergillosis (ABPA), which requires treatment with long regimens of oral steroids and oral anti-fungal medications with significant systemic side effects.  Administering anti-fungal agents directly to the lung offers the potential of high therapeutic concentration in the lung and reduced systemic side effects". LIFE has resported a much  higher incidence of up to 50% of  CF patients having aspergillosis infections (report and article).

This follows the approval in early June by the FDA in the USA, of another new drug for cystic fibrosis from Vertex Pharmaceuticals that might eventually help nearly half of patients with cystic fibrosis. According to the manufacturers this drug works directly to counteract the genetic defect that causes the disease, rather than just treat the symptoms more info.

View press release.